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Tuberculosis (TB) is caused by infection with 
Mycobacterium tuberculosis (M. Tuberculosis, MTB) and 
despite ongoing global efforts for its eradication there were 
still an estimated 8.7 million new cases and 1.4 million 
deaths worldwide in 2011 (1).  Co-infection with HIV 
caused 13% new actively infected people resulting in a 
high mortality rate (48.6 %) among these patients (2).  TB is 
therefore considered as one of the leading causes of death 
due to infectious diseases worldwide despite the 
availability of effective and extensive therapeutic 
approaches (3, 4).   
Two TB-related conditions have been reported, namely, 
active TB and a latent form of TB infection whereby MTB 
survives in the body without causing overt signs or 
symptoms of the disease.   People with latent TB infection 
are not infectious and cannot spread the TB bacteria to 
others.  However, if TB bacteria become active in the body 
and multiply, the person will go from having a latent TB 
infection to being sick with TB disease and becoming 
infective.  This unmasking of the latent disease may be 
idiopathic or the result of immunosuppression either from 
disease directly or from the use of drugs for treatment of 
other diseases (5).  
The first line of defense against MTB is provided by 
alveolar macrophages, which ingest and sequester the 
bacilli within granulomatous structures.  The control and 
resolution of the infection also require activated T 
lymphocytes (6) and Th1 cytokines (7). Interestingly, 
genetic defects within the IL-12/IFN− pathway have been 
found in patients with mendelian susceptibility to 
mycobacterial disease (MSMD) caused by live BCG vaccine 
or NTM species.  This highlights the crucial role of IL-
12/IFN− axis in the immune regulation of TB (8).  
Sarcoidosis is considered an autoimmune disease 
characterized by multisystem disorder of unclear etiology 
that involves any organ, but most commonly the lungs and 
the intrathoracic lymph nodes although the heart, skin and 
central nervous system are frequently affected (9). Despite 
the first clinical description of sarcoidosis over 120 years 
ago, little is known about the pathogenesis of this disease 
(10).  A genetic predisposition to sarcoidosis is evident 
from epidemiological studies of familial aggregation, 
differences in disease susceptibility and severity between 
racial groups and the significantly increased incidence of 
sarcoidosis in monozygotic twins of affected individuals 
compared to other siblings (11, 12).  More recent results 
have provided further insights into the genetic risks for 
TANAFFOS  
Mortaz E, et al.   7 
Tanaffos 2013; 12(4): 6-9 
sarcoidosis and how the genetic makeup of a patient 
(genotype) determines the clinical presentation and 
outcome (phenotype) of an individual’s disease (10, 13).  
However, it is clear that no one gene drives sarcoidosis and 
that the genetic risk is composed of numerous genes 
having a small effect and that it is the combination of these 
small individual gene effects that influences disease 
predisposition (13). 
Diagnosing sarcoidosis in patients with a high TB 
burden poses a significant global challenge particularly in 
developing countries where there is high prevalence of 
tuberculosis.  Both tuberculosis and sarcoidosis are 
granulomatous diseases; however, TB results in a caseating 
granuloma as opposed to sarcoidosis, which presents with 
a non-caseating epithelioid cell granuloma.   New cases of 
sarcoidosis are increasingly being diagnosed in areas 
endemic for TB due to increased awareness and better 
availability of diagnostic modalities (14).  As described 
above, sarcoidosis is a multisystem disorder of unknown 
etiology, characterized by the presence of non-caseating 
granuloma (15). In the clinical situation, it is often difficult 
to differentiate sarcoidosis from tuberculosis, especially 
when caseous necrosis is not seen and acid-fast staining is 
negative in biopsy tissue of TB patients.   
Histopathologic definitions of sarcoidosis are 
inadequate, because sarcoid granulomas are not 
pathologically distinct and cannot be distinguished by 
simple microscopic or histochemical analysis from 
granulomas due to other causes (16).  Non-specific 
constitutional symptoms such as fever, fatigue, malaise 
and weight loss are present in approximately one-third of 
patients whilst a chest X-ray usually shows hilar and 
mediastinal lymphadenopathy.  Other characteristic 
findings include interstitial lung disease, or occasional 
calcification of affected lymph nodes (17).  Although the 
lungs are the most common sites of inflammation, 
sarcoidosis can also involve other organs such as the eyes 
(intraocular and adnexal), skin, lymph nodes, salivary 
glands, heart, spleen, liver, and the nervous system (18).   
MTB as a possible cause of sarcoidosis has been 
extensively studied (19-21).  Granulomas form in the lungs 
as a result of the immune response to inhaled MTB and 
serve as the central site of host-pathogen interaction during 
MTB infection.  The host typically develops several 
granulomas based on the number of inhaled bacteria (22, 
23).  Granulomatous inflammation in sarcoidosis is 
believed to be caused by the presence of an unknown 
persistent poorly degradable antigen in conjunction with a 
strong and non-resolving subsequent host response (24, 
25).  Studies from India have reported patients with TB 
preceding the development of sarcoidosis or concurrent 
presence of both diseases (26-28).  This supports other 
evidence describing the coexistence of sarcoidosis and 
tuberculosis in the same patient (28, 29).  The diagnosis of 
co-existent disease is established most securely when 
clinico-radiological findings are supported by histological 
evidence of widespread non-caseating granulomas (30).  
However, some TB tissues do not have caseous necrosis 
and even the distinction between caseation and 
noncaseation is not absolute.  MTB DNA detection in 
sarcoidosis samples by traditional PCR has been used for 
the pathological study of sarcoidosis; however, it is likely 
that real-time RT-qPCR analysis of specific mRNAs and 
microRNAs will be necessary to provide a sensitive, 
precise, and rapid diagnostic test for sarcoidosis in TB 
patients (4).  As a result, there is still no definitive 
conclusion as to the relationship of MTB with sarcoidosis 
(31-36).  
In conclusion, diagnosing sarcoidosis in patients with a 
high TB burden poses a significant global challenge.  
Current approaches to diagnosis indicate an increased 
prevalence of sarcoidosis in areas where MTB is endemic.  
Improved diagnostic tests including combinations of 
genetics, mRNA and microRNA profiles are likely to 
provide improved phenotyping of the various types of 
sarcoidosis.  Improved phenotyping of sarcoid patients 
may result in better personalized medicine for individuals 
leading to improved quality of life. 
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